Work to date has identified prostate-specific membrane antigen (PSMA)
as a membrane-bound glycoprotein with high specificity for prostatic e
pithelial cells. PSMA reacts with the monoclonal antibody 7E11.C5, whi
ch is present in serum, seminal fluid, and prostatic epithelial cells,
and is increased in its expression in the presence of a hormone refra
ctory state associated with prostatic cancer. This report confirms the
se results and further documents the presence of the monoclonal antibo
dy 3F5.4G6, which reacts with the extracellular domain of PSMA. This r
egion of PSMA is also an element present in a truncated version of the
protein, so-called PSM'. Immune precipitation with either 7E11.C5 or
3F5.4G6 yields an isolated protein species that are reactive with the
reciprocal antibody in Western blot analysis. Thus, 3F5.4G6 recognizes
the same PSMA protein as does 7E11.C5, but at different epitopes on e
ssentially opposite ends of the molecule. These two antibodies are wel
l suited for use in a sandwich immunoassay, either one as a capture or
detection antibody. Current work on this is underway. This report als
o confirms that 7E11.C5 Western blots for PSMA are negative with norma
l human brain tissue. The monoclonal antibody 9H10 does not react with
3F5.4G6 or with 7E11.C5 in studies conducted herein. Moreover, 3F5.4G
6 reacts with PSMA found in the LNCaP cell line, but not DU-145 or PC3
, which lack PSMA. (C) 1996 Wiley-Liss, Inc.